nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—DRD5—attention deficit hyperactivity disorder	0.154	0.199	CbGaD
Ziprasidone—ADRA2C—attention deficit hyperactivity disorder	0.145	0.187	CbGaD
Ziprasidone—DRD4—attention deficit hyperactivity disorder	0.0789	0.102	CbGaD
Ziprasidone—HTR1B—attention deficit hyperactivity disorder	0.0701	0.0903	CbGaD
Ziprasidone—DRD3—attention deficit hyperactivity disorder	0.068	0.0876	CbGaD
Ziprasidone—DRD1—attention deficit hyperactivity disorder	0.0668	0.086	CbGaD
Ziprasidone—ADRA2A—attention deficit hyperactivity disorder	0.0621	0.0799	CbGaD
Ziprasidone—SLC6A4—attention deficit hyperactivity disorder	0.0473	0.061	CbGaD
Ziprasidone—DRD2—attention deficit hyperactivity disorder	0.0471	0.0606	CbGaD
Ziprasidone—HTR2A—attention deficit hyperactivity disorder	0.0364	0.0469	CbGaD
Ziprasidone—HTR7—locus ceruleus—attention deficit hyperactivity disorder	0.00376	0.063	CbGeAlD
Ziprasidone—HTR2A—locus ceruleus—attention deficit hyperactivity disorder	0.00234	0.0393	CbGeAlD
Ziprasidone—HTR7—autonomic nervous system—attention deficit hyperactivity disorder	0.002	0.0335	CbGeAlD
Ziprasidone—Lurasidone—ADRA2C—attention deficit hyperactivity disorder	0.00169	0.24	CrCbGaD
Ziprasidone—HTR1E—forebrain—attention deficit hyperactivity disorder	0.00128	0.0214	CbGeAlD
Ziprasidone—HTR2A—autonomic nervous system—attention deficit hyperactivity disorder	0.00125	0.0209	CbGeAlD
Ziprasidone—HTR6—forebrain—attention deficit hyperactivity disorder	0.001	0.0168	CbGeAlD
Ziprasidone—DRD5—forebrain—attention deficit hyperactivity disorder	0.000975	0.0163	CbGeAlD
Ziprasidone—H1F0—forebrain—attention deficit hyperactivity disorder	0.000755	0.0126	CbGeAlD
Ziprasidone—DRD1—forebrain—attention deficit hyperactivity disorder	0.000745	0.0125	CbGeAlD
Ziprasidone—Lurasidone—ADRA2A—attention deficit hyperactivity disorder	0.000723	0.103	CrCbGaD
Ziprasidone—HTR3A—forebrain—attention deficit hyperactivity disorder	0.00072	0.012	CbGeAlD
Ziprasidone—HTR1E—nervous system—attention deficit hyperactivity disorder	0.000693	0.0116	CbGeAlD
Ziprasidone—HTR1E—central nervous system—attention deficit hyperactivity disorder	0.000667	0.0112	CbGeAlD
Ziprasidone—H1F0—cardiovascular system—attention deficit hyperactivity disorder	0.000638	0.0107	CbGeAlD
Ziprasidone—DRD4—brain—attention deficit hyperactivity disorder	0.000614	0.0103	CbGeAlD
Ziprasidone—CHRM4—nervous system—attention deficit hyperactivity disorder	0.000608	0.0102	CbGeAlD
Ziprasidone—HTR1B—forebrain—attention deficit hyperactivity disorder	0.000604	0.0101	CbGeAlD
Ziprasidone—CHRM2—forebrain—attention deficit hyperactivity disorder	0.0006	0.0101	CbGeAlD
Ziprasidone—CHRM4—central nervous system—attention deficit hyperactivity disorder	0.000585	0.00979	CbGeAlD
Ziprasidone—HTR1D—forebrain—attention deficit hyperactivity disorder	0.000584	0.00979	CbGeAlD
Ziprasidone—HTR2C—forebrain—attention deficit hyperactivity disorder	0.000579	0.00969	CbGeAlD
Ziprasidone—DRD3—nervous system—attention deficit hyperactivity disorder	0.000565	0.00946	CbGeAlD
Ziprasidone—SLC6A4—forebrain—attention deficit hyperactivity disorder	0.000549	0.00919	CbGeAlD
Ziprasidone—Lurasidone—DRD2—attention deficit hyperactivity disorder	0.000549	0.0778	CrCbGaD
Ziprasidone—CHRM1—forebrain—attention deficit hyperactivity disorder	0.000547	0.00915	CbGeAlD
Ziprasidone—DRD3—central nervous system—attention deficit hyperactivity disorder	0.000544	0.00911	CbGeAlD
Ziprasidone—HTR6—nervous system—attention deficit hyperactivity disorder	0.000544	0.0091	CbGeAlD
Ziprasidone—HTR1E—brain—attention deficit hyperactivity disorder	0.00053	0.00887	CbGeAlD
Ziprasidone—DRD5—nervous system—attention deficit hyperactivity disorder	0.000529	0.00886	CbGeAlD
Ziprasidone—HTR6—central nervous system—attention deficit hyperactivity disorder	0.000523	0.00877	CbGeAlD
Ziprasidone—HTR1B—cardiovascular system—attention deficit hyperactivity disorder	0.00051	0.00855	CbGeAlD
Ziprasidone—DRD5—central nervous system—attention deficit hyperactivity disorder	0.00051	0.00853	CbGeAlD
Ziprasidone—CHRM2—cardiovascular system—attention deficit hyperactivity disorder	0.000508	0.0085	CbGeAlD
Ziprasidone—H1F0—midbrain—attention deficit hyperactivity disorder	0.000498	0.00834	CbGeAlD
Ziprasidone—HTR1D—cardiovascular system—attention deficit hyperactivity disorder	0.000494	0.00828	CbGeAlD
Ziprasidone—DRD1—midbrain—attention deficit hyperactivity disorder	0.000492	0.00824	CbGeAlD
Ziprasidone—CHRM3—forebrain—attention deficit hyperactivity disorder	0.000489	0.00819	CbGeAlD
Ziprasidone—HTR1A—forebrain—attention deficit hyperactivity disorder	0.000487	0.00816	CbGeAlD
Ziprasidone—CHRM5—nervous system—attention deficit hyperactivity disorder	0.000475	0.00795	CbGeAlD
Ziprasidone—HTR7—forebrain—attention deficit hyperactivity disorder	0.000466	0.0078	CbGeAlD
Ziprasidone—CHRM4—brain—attention deficit hyperactivity disorder	0.000464	0.00778	CbGeAlD
Ziprasidone—CHRM1—cardiovascular system—attention deficit hyperactivity disorder	0.000462	0.00774	CbGeAlD
Ziprasidone—CHRM5—central nervous system—attention deficit hyperactivity disorder	0.000457	0.00766	CbGeAlD
Ziprasidone—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.000449	0.00752	CbGeAlD
Ziprasidone—DRD2—forebrain—attention deficit hyperactivity disorder	0.00044	0.00737	CbGeAlD
Ziprasidone—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.000434	0.00727	CbGeAlD
Ziprasidone—KCNH2—forebrain—attention deficit hyperactivity disorder	0.000434	0.00726	CbGeAlD
Ziprasidone—DRD3—brain—attention deficit hyperactivity disorder	0.000432	0.00723	CbGeAlD
Ziprasidone—Aripiprazole—DRD5—attention deficit hyperactivity disorder	0.000429	0.0608	CrCbGaD
Ziprasidone—Lurasidone—HTR2A—attention deficit hyperactivity disorder	0.000424	0.0602	CrCbGaD
Ziprasidone—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.000418	0.007	CbGeAlD
Ziprasidone—HTR6—brain—attention deficit hyperactivity disorder	0.000416	0.00696	CbGeAlD
Ziprasidone—HTR1A—cardiovascular system—attention deficit hyperactivity disorder	0.000412	0.0069	CbGeAlD
Ziprasidone—H1F0—nervous system—attention deficit hyperactivity disorder	0.00041	0.00686	CbGeAlD
Ziprasidone—DRD5—brain—attention deficit hyperactivity disorder	0.000405	0.00677	CbGeAlD
Ziprasidone—DRD1—nervous system—attention deficit hyperactivity disorder	0.000404	0.00677	CbGeAlD
Ziprasidone—Aripiprazole—ADRA2C—attention deficit hyperactivity disorder	0.000404	0.0573	CrCbGaD
Ziprasidone—HTR1B—midbrain—attention deficit hyperactivity disorder	0.000399	0.00667	CbGeAlD
Ziprasidone—H1F0—central nervous system—attention deficit hyperactivity disorder	0.000394	0.0066	CbGeAlD
Ziprasidone—HTR7—cardiovascular system—attention deficit hyperactivity disorder	0.000394	0.00659	CbGeAlD
Ziprasidone—HTR3A—nervous system—attention deficit hyperactivity disorder	0.000391	0.00654	CbGeAlD
Ziprasidone—DRD1—central nervous system—attention deficit hyperactivity disorder	0.000389	0.00652	CbGeAlD
Ziprasidone—HTR1D—midbrain—attention deficit hyperactivity disorder	0.000386	0.00646	CbGeAlD
Ziprasidone—H1F0—cerebellum—attention deficit hyperactivity disorder	0.000385	0.00645	CbGeAlD
Ziprasidone—HTR2C—midbrain—attention deficit hyperactivity disorder	0.000382	0.0064	CbGeAlD
Ziprasidone—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.00038	0.00636	CbGeAlD
Ziprasidone—HTR3A—central nervous system—attention deficit hyperactivity disorder	0.000376	0.0063	CbGeAlD
Ziprasidone—KCNH2—cardiovascular system—attention deficit hyperactivity disorder	0.000367	0.00614	CbGeAlD
Ziprasidone—CHRM5—brain—attention deficit hyperactivity disorder	0.000363	0.00608	CbGeAlD
Ziprasidone—SLC6A4—midbrain—attention deficit hyperactivity disorder	0.000362	0.00607	CbGeAlD
Ziprasidone—HRH1—forebrain—attention deficit hyperactivity disorder	0.000348	0.00582	CbGeAlD
Ziprasidone—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.000341	0.00572	CbGeAlD
Ziprasidone—ADRA1B—brain—attention deficit hyperactivity disorder	0.000332	0.00555	CbGeAlD
Ziprasidone—HTR1B—nervous system—attention deficit hyperactivity disorder	0.000328	0.00549	CbGeAlD
Ziprasidone—CHRM2—nervous system—attention deficit hyperactivity disorder	0.000326	0.00546	CbGeAlD
Ziprasidone—HTR1A—midbrain—attention deficit hyperactivity disorder	0.000322	0.00539	CbGeAlD
Ziprasidone—HTR1D—nervous system—attention deficit hyperactivity disorder	0.000317	0.00531	CbGeAlD
Ziprasidone—HTR1B—central nervous system—attention deficit hyperactivity disorder	0.000316	0.00528	CbGeAlD
Ziprasidone—HTR2C—nervous system—attention deficit hyperactivity disorder	0.000314	0.00526	CbGeAlD
Ziprasidone—CHRM2—central nervous system—attention deficit hyperactivity disorder	0.000314	0.00525	CbGeAlD
Ziprasidone—H1F0—brain—attention deficit hyperactivity disorder	0.000313	0.00524	CbGeAlD
Ziprasidone—DRD1—brain—attention deficit hyperactivity disorder	0.000309	0.00518	CbGeAlD
Ziprasidone—HTR7—midbrain—attention deficit hyperactivity disorder	0.000307	0.00515	CbGeAlD
Ziprasidone—HTR1D—central nervous system—attention deficit hyperactivity disorder	0.000305	0.00511	CbGeAlD
Ziprasidone—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.000303	0.00507	CbGeAlD
Ziprasidone—HTR3A—brain—attention deficit hyperactivity disorder	0.000299	0.005	CbGeAlD
Ziprasidone—SLC6A4—nervous system—attention deficit hyperactivity disorder	0.000298	0.00499	CbGeAlD
Ziprasidone—CHRM1—nervous system—attention deficit hyperactivity disorder	0.000297	0.00497	CbGeAlD
Ziprasidone—DRD2—midbrain—attention deficit hyperactivity disorder	0.000291	0.00487	CbGeAlD
Ziprasidone—HTR2A—forebrain—attention deficit hyperactivity disorder	0.00029	0.00486	CbGeAlD
Ziprasidone—SLC6A4—central nervous system—attention deficit hyperactivity disorder	0.000287	0.0048	CbGeAlD
Ziprasidone—KCNH2—midbrain—attention deficit hyperactivity disorder	0.000286	0.0048	CbGeAlD
Ziprasidone—CHRM1—central nervous system—attention deficit hyperactivity disorder	0.000286	0.00478	CbGeAlD
Ziprasidone—ADRA2C—midbrain—attention deficit hyperactivity disorder	0.000283	0.00473	CbGeAlD
Ziprasidone—CHRM3—nervous system—attention deficit hyperactivity disorder	0.000266	0.00445	CbGeAlD
Ziprasidone—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000264	0.00443	CbGeAlD
Ziprasidone—HTR1A—nervous system—attention deficit hyperactivity disorder	0.000264	0.00443	CbGeAlD
Ziprasidone—CHRM3—central nervous system—attention deficit hyperactivity disorder	0.000256	0.00428	CbGeAlD
Ziprasidone—HTR1A—central nervous system—attention deficit hyperactivity disorder	0.000255	0.00426	CbGeAlD
Ziprasidone—HTR7—nervous system—attention deficit hyperactivity disorder	0.000253	0.00423	CbGeAlD
Ziprasidone—HTR1B—brain—attention deficit hyperactivity disorder	0.00025	0.00419	CbGeAlD
Ziprasidone—CHRM2—brain—attention deficit hyperactivity disorder	0.000249	0.00417	CbGeAlD
Ziprasidone—HTR1A—cerebellum—attention deficit hyperactivity disorder	0.000249	0.00417	CbGeAlD
Ziprasidone—HTR2A—cardiovascular system—attention deficit hyperactivity disorder	0.000246	0.00411	CbGeAlD
Ziprasidone—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000244	0.00408	CbGeAlD
Ziprasidone—HTR7—central nervous system—attention deficit hyperactivity disorder	0.000243	0.00407	CbGeAlD
Ziprasidone—HTR1D—brain—attention deficit hyperactivity disorder	0.000243	0.00406	CbGeAlD
Ziprasidone—HTR2C—brain—attention deficit hyperactivity disorder	0.00024	0.00402	CbGeAlD
Ziprasidone—DRD2—nervous system—attention deficit hyperactivity disorder	0.000239	0.004	CbGeAlD
Ziprasidone—Clozapine—HRH3—attention deficit hyperactivity disorder	0.000238	0.0338	CrCbGaD
Ziprasidone—HTR7—cerebellum—attention deficit hyperactivity disorder	0.000238	0.00398	CbGeAlD
Ziprasidone—KCNH2—nervous system—attention deficit hyperactivity disorder	0.000235	0.00394	CbGeAlD
Ziprasidone—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000235	0.00393	CbGeAlD
Ziprasidone—ADRA2C—nervous system—attention deficit hyperactivity disorder	0.000232	0.00389	CbGeAlD
Ziprasidone—DRD2—central nervous system—attention deficit hyperactivity disorder	0.00023	0.00385	CbGeAlD
Ziprasidone—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000229	0.00384	CbGeAlD
Ziprasidone—SLC6A4—brain—attention deficit hyperactivity disorder	0.000228	0.00381	CbGeAlD
Ziprasidone—CHRM1—brain—attention deficit hyperactivity disorder	0.000227	0.0038	CbGeAlD
Ziprasidone—KCNH2—central nervous system—attention deficit hyperactivity disorder	0.000227	0.0038	CbGeAlD
Ziprasidone—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000225	0.00378	CbGeAlD
Ziprasidone—DRD2—cerebellum—attention deficit hyperactivity disorder	0.000225	0.00377	CbGeAlD
Ziprasidone—ADRA2C—central nervous system—attention deficit hyperactivity disorder	0.000224	0.00374	CbGeAlD
Ziprasidone—KCNH2—cerebellum—attention deficit hyperactivity disorder	0.000222	0.00371	CbGeAlD
Ziprasidone—Aripiprazole—DRD4—attention deficit hyperactivity disorder	0.000219	0.0311	CrCbGaD
Ziprasidone—ADRA2C—cerebellum—attention deficit hyperactivity disorder	0.000219	0.00366	CbGeAlD
Ziprasidone—Clozapine—ADRA2C—attention deficit hyperactivity disorder	0.000217	0.0308	CrCbGaD
Ziprasidone—CHRM3—brain—attention deficit hyperactivity disorder	0.000203	0.0034	CbGeAlD
Ziprasidone—HTR1A—brain—attention deficit hyperactivity disorder	0.000202	0.00338	CbGeAlD
Ziprasidone—Aripiprazole—HTR1B—attention deficit hyperactivity disorder	0.000195	0.0276	CrCbGaD
Ziprasidone—HTR7—brain—attention deficit hyperactivity disorder	0.000193	0.00323	CbGeAlD
Ziprasidone—HTR2A—midbrain—attention deficit hyperactivity disorder	0.000192	0.00321	CbGeAlD
Ziprasidone—Aripiprazole—DRD3—attention deficit hyperactivity disorder	0.000189	0.0268	CrCbGaD
Ziprasidone—HRH1—nervous system—attention deficit hyperactivity disorder	0.000189	0.00316	CbGeAlD
Ziprasidone—ADRA1A—brain—attention deficit hyperactivity disorder	0.000186	0.00312	CbGeAlD
Ziprasidone—Aripiprazole—DRD1—attention deficit hyperactivity disorder	0.000186	0.0263	CrCbGaD
Ziprasidone—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.000185	0.0031	CbGeAlD
Ziprasidone—DRD2—brain—attention deficit hyperactivity disorder	0.000183	0.00306	CbGeAlD
Ziprasidone—HRH1—central nervous system—attention deficit hyperactivity disorder	0.000182	0.00304	CbGeAlD
Ziprasidone—KCNH2—brain—attention deficit hyperactivity disorder	0.00018	0.00301	CbGeAlD
Ziprasidone—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000178	0.00299	CbGeAlD
Ziprasidone—ADRA2C—brain—attention deficit hyperactivity disorder	0.000178	0.00297	CbGeAlD
Ziprasidone—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000174	0.00292	CbGeAlD
Ziprasidone—Aripiprazole—ADRA2A—attention deficit hyperactivity disorder	0.000172	0.0245	CrCbGaD
Ziprasidone—Trazodone—ADRA2A—attention deficit hyperactivity disorder	0.000172	0.0244	CrCbGaD
Ziprasidone—HTR2A—nervous system—attention deficit hyperactivity disorder	0.000158	0.00264	CbGeAlD
Ziprasidone—HTR2A—central nervous system—attention deficit hyperactivity disorder	0.000152	0.00254	CbGeAlD
Ziprasidone—HTR2A—cerebellum—attention deficit hyperactivity disorder	0.000148	0.00248	CbGeAlD
Ziprasidone—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.000146	0.00244	CbGeAlD
Ziprasidone—HRH1—brain—attention deficit hyperactivity disorder	0.000144	0.00242	CbGeAlD
Ziprasidone—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000144	0.0024	CbGeAlD
Ziprasidone—ADRA2A—brain—attention deficit hyperactivity disorder	0.000142	0.00237	CbGeAlD
Ziprasidone—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00014	0.00235	CbGeAlD
Ziprasidone—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000138	0.00231	CbGeAlD
Ziprasidone—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000135	0.00226	CbGeAlD
Ziprasidone—Aripiprazole—SLC6A4—attention deficit hyperactivity disorder	0.000132	0.0187	CrCbGaD
Ziprasidone—Trazodone—SLC6A4—attention deficit hyperactivity disorder	0.000131	0.0186	CrCbGaD
Ziprasidone—Aripiprazole—DRD2—attention deficit hyperactivity disorder	0.000131	0.0186	CrCbGaD
Ziprasidone—HTR2A—brain—attention deficit hyperactivity disorder	0.00012	0.00202	CbGeAlD
Ziprasidone—Clozapine—DRD4—attention deficit hyperactivity disorder	0.000118	0.0167	CrCbGaD
Ziprasidone—CYP2D6—brain—attention deficit hyperactivity disorder	0.00011	0.00184	CbGeAlD
Ziprasidone—Clozapine—HTR1B—attention deficit hyperactivity disorder	0.000105	0.0149	CrCbGaD
Ziprasidone—Clozapine—DRD3—attention deficit hyperactivity disorder	0.000102	0.0144	CrCbGaD
Ziprasidone—Aripiprazole—HTR2A—attention deficit hyperactivity disorder	0.000101	0.0143	CrCbGaD
Ziprasidone—Trazodone—HTR2A—attention deficit hyperactivity disorder	0.000101	0.0143	CrCbGaD
Ziprasidone—Clozapine—DRD1—attention deficit hyperactivity disorder	9.98e-05	0.0142	CrCbGaD
Ziprasidone—Clozapine—ADRA2A—attention deficit hyperactivity disorder	9.27e-05	0.0132	CrCbGaD
Ziprasidone—Clozapine—DRD2—attention deficit hyperactivity disorder	7.03e-05	0.00998	CrCbGaD
Ziprasidone—Clozapine—HTR2A—attention deficit hyperactivity disorder	5.43e-05	0.00771	CrCbGaD
Ziprasidone—DRD4—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.68e-06	4.26e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.65e-06	4.24e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.62e-06	4.22e-05	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	6.59e-06	4.2e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.59e-06	4.2e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.56e-06	4.18e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.5e-06	4.15e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.47e-06	4.12e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.47e-06	4.12e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.46e-06	4.12e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.43e-06	4.1e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.42e-06	4.09e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.42e-06	4.09e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.42e-06	4.09e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	6.38e-06	4.07e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.38e-06	4.07e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.37e-06	4.06e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.36e-06	4.06e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.36e-06	4.06e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	6.33e-06	4.03e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.31e-06	4.02e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.28e-06	4e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	6.28e-06	4e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.24e-06	3.98e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.23e-06	3.97e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.23e-06	3.97e-05	CbGpPWpGaD
Ziprasidone—HTR1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.21e-06	3.96e-05	CbGpPWpGaD
Ziprasidone—HTR2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.18e-06	3.94e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.16e-06	3.93e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.14e-06	3.92e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.11e-06	3.9e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.06e-06	3.86e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.05e-06	3.86e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	6.03e-06	3.84e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.01e-06	3.83e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.01e-06	3.83e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.98e-06	3.81e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.93e-06	3.78e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.93e-06	3.78e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.91e-06	3.77e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.87e-06	3.74e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.86e-06	3.73e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	5.85e-06	3.73e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.85e-06	3.73e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.84e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.84e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.84e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.83e-06	3.72e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.81e-06	3.7e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.8e-06	3.7e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.77e-06	3.68e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.76e-06	3.67e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	5.75e-06	3.67e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.74e-06	3.66e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.72e-06	3.65e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.67e-06	3.61e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.65e-06	3.6e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.65e-06	3.6e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.64e-06	3.59e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.62e-06	3.59e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.61e-06	3.58e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.56e-06	3.55e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.56e-06	3.55e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.53e-06	3.52e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.46e-06	3.48e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.45e-06	3.48e-05	CbGpPWpGaD
Ziprasidone—DRD2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.45e-06	3.47e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.45e-06	3.47e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.43e-06	3.46e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.4e-06	3.44e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	5.39e-06	3.44e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.37e-06	3.42e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.35e-06	3.41e-05	CbGpPWpGaD
Ziprasidone—HRH1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.35e-06	3.41e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.35e-06	3.41e-05	CbGpPWpGaD
Ziprasidone—CHRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.33e-06	3.4e-05	CbGpPWpGaD
Ziprasidone—CHRM3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.32e-06	3.39e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.29e-06	3.37e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.29e-06	3.37e-05	CbGpPWpGaD
Ziprasidone—CHRM2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.27e-06	3.36e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.26e-06	3.35e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.25e-06	3.35e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	5.25e-06	3.35e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	5.25e-06	3.35e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.23e-06	3.33e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.17e-06	3.3e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.17e-06	3.29e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.14e-06	3.28e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.13e-06	3.27e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	5.1e-06	3.25e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.1e-06	3.25e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.1e-06	3.25e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.09e-06	3.24e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.08e-06	3.24e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.04e-06	3.22e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Hemostasis—EP300—attention deficit hyperactivity disorder	5.04e-06	3.21e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.03e-06	3.21e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.02e-06	3.2e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.01e-06	3.19e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5e-06	3.19e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5e-06	3.19e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.95e-06	3.16e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.95e-06	3.16e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.94e-06	3.15e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.94e-06	3.15e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.93e-06	3.14e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.92e-06	3.14e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—COMT—attention deficit hyperactivity disorder	4.9e-06	3.13e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.88e-06	3.11e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—MAOA—attention deficit hyperactivity disorder	4.87e-06	3.1e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.86e-06	3.1e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.86e-06	3.1e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.84e-06	3.09e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.83e-06	3.08e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.78e-06	3.05e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.77e-06	3.04e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.77e-06	3.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—COMT—attention deficit hyperactivity disorder	4.76e-06	3.04e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.75e-06	3.03e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.73e-06	3.02e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—MAOA—attention deficit hyperactivity disorder	4.73e-06	3.01e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.69e-06	2.99e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.68e-06	2.98e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.68e-06	2.98e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.66e-06	2.97e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.65e-06	2.96e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.62e-06	2.94e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.6e-06	2.94e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.6e-06	2.93e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.59e-06	2.93e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	4.59e-06	2.93e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.54e-06	2.9e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.54e-06	2.89e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.53e-06	2.89e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.53e-06	2.89e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.52e-06	2.88e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.5e-06	2.87e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.5e-06	2.87e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.49e-06	2.86e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.48e-06	2.86e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.46e-06	2.85e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.46e-06	2.85e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.46e-06	2.84e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.45e-06	2.84e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.45e-06	2.84e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.45e-06	2.84e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.44e-06	2.83e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	4.43e-06	2.82e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.43e-06	2.82e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.41e-06	2.81e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.4e-06	2.8e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.39e-06	2.8e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.38e-06	2.79e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.37e-06	2.79e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	4.37e-06	2.79e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.37e-06	2.79e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.33e-06	2.76e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.32e-06	2.75e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.3e-06	2.74e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	4.27e-06	2.72e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.24e-06	2.71e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—COMT—attention deficit hyperactivity disorder	4.21e-06	2.69e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—MAOA—attention deficit hyperactivity disorder	4.18e-06	2.67e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	4.16e-06	2.65e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.16e-06	2.65e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	4.13e-06	2.63e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.11e-06	2.62e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.1e-06	2.61e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	4.09e-06	2.61e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	4.09e-06	2.61e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.09e-06	2.6e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.07e-06	2.6e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.06e-06	2.59e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.03e-06	2.57e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.02e-06	2.56e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	4.01e-06	2.56e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.94e-06	2.51e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.87e-06	2.47e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	3.87e-06	2.47e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	3.84e-06	2.45e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.82e-06	2.44e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.8e-06	2.43e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.74e-06	2.38e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	3.54e-06	2.26e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.52e-06	2.25e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	3.52e-06	2.25e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	3.52e-06	2.24e-05	CbGpPWpGaD
Ziprasidone—HTR1E—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.49e-06	2.22e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	3.47e-06	2.21e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.45e-06	2.2e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.33e-06	2.12e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.32e-06	2.12e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.31e-06	2.11e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.22e-06	2.05e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.22e-06	2.05e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.17e-06	2.02e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.17e-06	2.02e-05	CbGpPWpGaD
Ziprasidone—DRD5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	3.09e-06	1.97e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.92e-06	1.86e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.87e-06	1.83e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.86e-06	1.82e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.85e-06	1.82e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.82e-06	1.8e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.82e-06	1.8e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.82e-06	1.8e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	2.72e-06	1.73e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.72e-06	1.73e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.68e-06	1.71e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	2.68e-06	1.71e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.62e-06	1.67e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	2.52e-06	1.61e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	2.5e-06	1.6e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.49e-06	1.59e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.38e-06	1.52e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.38e-06	1.52e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.37e-06	1.51e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.32e-06	1.48e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.28e-06	1.45e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.25e-06	1.43e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.17e-06	1.39e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.15e-06	1.37e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	2.13e-06	1.36e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	2.12e-06	1.35e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—EP300—attention deficit hyperactivity disorder	2.1e-06	1.34e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.07e-06	1.32e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	2.06e-06	1.31e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.05e-06	1.31e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—EP300—attention deficit hyperactivity disorder	2.04e-06	1.3e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.02e-06	1.29e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.83e-06	1.17e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—EP300—attention deficit hyperactivity disorder	1.81e-06	1.15e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.76e-06	1.12e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.76e-06	1.12e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.71e-06	1.09e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.68e-06	1.07e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	1.66e-06	1.06e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	1.65e-06	1.05e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	1.64e-06	1.04e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.55e-06	9.88e-06	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.52e-06	9.72e-06	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.52e-06	9.7e-06	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	1.52e-06	9.69e-06	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.52e-06	9.66e-06	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.51e-06	9.63e-06	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.5e-06	9.54e-06	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.49e-06	9.51e-06	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.39e-06	8.84e-06	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	1.08e-06	6.89e-06	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	9.15e-07	5.84e-06	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	7.06e-07	4.5e-06	CbGpPWpGaD
